Navigation Links
Breakthrough Prostate Cancer Diagnostics

NEW YORK, June 19, 2012 /PRNewswire/ -- More precise prostate cancer diagnostics could be right around the corner, thanks to evolving MRI capabilities. Netherlands MRI and Urogenital disease specialist, Dr. Jelle Barentsz, is making significant headway in improving MRI technology to accurately diagnose and stage prostate cancer tumors with a success rate of 90 percent.

(Photo: )

Detected through a simple blood test, a spike in PSA level is typically the first indicator of the potential presence of prostate cancer. A prostate cancer biopsy is then performed through a series of 12, sometimes painful, needle insertions. Despite these procedures, current prostate cancer staging abilities are somewhat limited and the needle biopsies do not always clearly define the tumor's boundaries.

Dr. David Samadi, leading U.S. prostate cancer surgeon, details how Dr. Barentsz's MRI advancements could significantly improve the ability to accurately define the degree of a man's prostate cancer. "With current diagnostics I don't get a perfect picture of the prostate cancer until I see it first-hand during robotic prostate surgery. The microscopic clarity of Dr. Barentsz's new MRI technology may soon afford the opportunity to truly see the prostate, the cancer, and its borders before surgery is performed," Dr. Samadi explained.

More accurate MRI imaging has the potential to improve prostate cancer diagnosis in two major ways. First, needle biopsy could be reduced to one or two highly targeted insertions based on exact imaging of the tumor location. Second, more precise imaging could reduce the need for biopsy in men where no prostate abnormalities are visualized.

Some critics argue that routine PSA screening leads to unnecessary biopsies as not all elevated PSA levels are caused by prostate cancer. Dr. Barentsz believes prostate cancer biopsies could be reduced by as much as two-thirds with his more accurate imaging.

At the end of 2011, Dr. Samadi traveled to the Netherlands to work side-by-side with Dr. Barentsz at The Dutch Radboud University Nijmegen Medical Center. During his stay, Dr. Samadi performed multiple, live robotic prostatectomy surgeries to train local experts on his custom Samadi Modified Advanced Robotic Technique (SMART) surgery

"While in the Netherlands I witnessed the exciting potential of Dr. Barentsz's advanced MRI imaging," Dr. Samadi said. "We were able to combine the power of his technology with the precision of my SMART surgery to yield very successful results. I truly believe that his efforts will have a great impact on the ability to diagnose and eliminate prostate cancer for patients globally."

Dr. David Samadi is Vice Chairman of the Department of Urology and Chief of Robotics and Minimally Invasive Surgery at Mount Sinai Medical Center. From his practice in New York City, Dr. Samadi often travels overseas to "treat and teach" his SMART surgery procedure and routinely welcomes international patients for surgery in the U.S. To date, over 4,000 men have benefited from the life-saving results of his skilled prostate removal surgery.

Related Links:

Related Videos:

PSA Test: Prostate Screening Saves Lives

Robotic Prostate Surgery SMART Technique

The Benefits of Robotic Prostate Cancer Surgery

Learn About Robotic Prostate Surgery

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Denton Vacuum Ships Breakthrough Wafer-level Optics Development System to Leading German R&D Organization
2. Global Pharmaceutical Leaders All Converging in Parsippany, New Jersey on September 11-12, 2012 for Breakthrough Event
3. Arkansas Prostate Cancer Center Earns High Honor of ACR-ASTRO Accreditation
4. CyberKnife® Prostate SBRT Outcomes and Quality of Life Data Presented at American Urological Association Meeting
5. Ventana licenses Gen-Probe IP for measuring ERG protein in prostate cancer patients
6. US HIFU to Showcase High Intensity Focused Ultrasound for the Treatment of Prostate Cancer at AUA
7. Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
8. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
9. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
10. Austrian Medical Center Upgrades Cancer Treatment System, Improves Patient Care with Elektas Agility Beam-shaping Device
11. European Hematology Association, American Society of Hematology, and the European Cancer Patient Coalition Issue an International Call to Action to Alleviate Drug Shortages
Post Your Comments:
(Date:11/30/2015)... , November 30, 2015 ... --> adds a 2015 ... 2010 - 2015 with comprehensive analysis ... range of deal types, such as ... alliances. . ...
(Date:11/30/2015)... , Nov. 30, 2015  Kevin Smith has ... Healthcare, a global pioneer in wireless monitoring of ... Boston, MA , Mr. Smith will be ... global commercial strategy.  He will also directly oversee ... build clinical evidence for SensiumVitals, the first early ...
(Date:11/30/2015)... , Nov. 30, 2015  The ... norm in U.S. medical imaging is on ... popular accountable care payer-provider contracts are set ... in their wake, alter provider-vendor relationships. The ... will push forward new purchasing frameworks in ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... Trevor and Taylor ... as they play for the chance to represent the United States. This hybrid ... to be a part of their journey in addition to offering corporate sponsors with ...
(Date:11/30/2015)... ... 01, 2015 , ... The National Association of Professional ... its VIP Woman of the Year Circle. She is recognized with this prestigious ... for professional women, boasting 850,000 members and over 200 operating Local Chapters. , ...
(Date:11/30/2015)... ... December 01, 2015 , ... ... Jones as a 2015-2016 inductee into its VIP Woman of the Year ... is the nation’s leading networking organization exclusively for professional women, boasting 850,000 members ...
(Date:11/30/2015)... ... December 01, 2015 , ... Live ... offer individual vision insurance plans on . The multi-carrier insurance exchange ... and review products, allowing consumers to compare, quote and match plans to meet ...
(Date:11/30/2015)... ... November 30, 2015 , ... Until now, the St. Louis Fetal ... MOMS (Management of Myelomeningocele Study) trial. One of these exclusion criteria was a BMI ... of 18.5 to 24.9 is considered normal, 25 - 29.9 is overweight and above ...
Breaking Medicine News(10 mins):